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Abstract
BACKGROUND—It is unclear whether therapy for human immunodeficiency virus type 1 
(HIV-1) should be initiated with a four-drug or two sequential three-drug regimens.
METHODS—In this multicenter trial we compared initial therapy involving four-drug regimens 
containing efavirenz and nelfinavir in combination with either didanosine and stavudine or 
zidovudine and lamivudine with therapy involving two consecutive three-drug regimens the first 
of which contained either efavirenz or nelfinavir.
RESULTS—A total of 980 subjects were followed for a median of 2.3 years. There was no 
significant difference in the occurrence of regimen failures between the group that received the 
four-drug regimen containing didanosine, stavudine, nelfinavir, and efavirenz and the groups that 
received the three-drug regimens beginning with didanosine, stavudine, and nelfinavir (hazard 
ratio for regimen failure, 1.24) or didanosine, stavudine, and efavirenz (hazard ratio, 1.01). There 
was no significant difference between the group that received the four-drug regimen containing 
zidovudine, lamivudine, nelfinavir, and efavirenz and the groups that received the three-drug 
regimens beginning with zidovudine, lamivudine, and nelfinavir (hazard ratio, 1.06) or 
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zidovudine, lamivudine, and efavirenz (hazard ratio, 1.45). A four-drug regimen was associated 
with a longer time to the first regimen failure than the three-drug regimens containing didanosine, 
stavudine, and nelfinavir (hazard ratio for a first regimen failure, 0.55); didanosine, stavudine, and 
efavirenz (hazard ratio, 0.63); or zidovudine, lamivudine, and nelfinavir (hazard ratio, 0.49), but 
not the three-drug regimen containing zidovudine, lamivudine, and efavirenz (hazard ratio, 1.21).
CONCLUSIONS—There was no significant difference in the duration of successful HIV-1 
treatment between a single four-drug regimen and two consecutive three-drug regimens. Among 
these treatment strategies, initiating therapy with the three-drug regimen of zidovudine, 
lamivudine, and efavirenz is the optimal choice.
Although many drugs are approved for the treatment of human immunodeficiency virus type 
1 (HIV-1) infection, the cause of the acquired immunodeficiency syndrome (AIDS), they 
belong to just four different classes: nucleoside or nucleotide reverse-transcriptase inhibitors 
(nucleoside analogues), nonnucleoside reverse-transcriptase inhibitors, protease inhibitors, 
and fusion inhibitors. Because cross-resistance within a class is common, the failure of the 
initial regimen used may compromise the success of future regimens. Indeed, the results of 
cohort studies suggest that a patient’s first treatment regimen has the greatest chance of 
success.1–3
Four-drug antiretroviral regimens containing drugs from three drug classes have the 
potential for increased potency but may also be associated with increased toxicity, decreased 
adherence, and the limitation of subsequent treatment options.4,5 Three-drug regimens 
containing drugs from only two classes may be less potent but more tolerable, and patients 
treated with regimens that exclude some classes of drugs may have a better response to 
subsequent treatments. We compared the use of four-drug regimens with the use of 
sequential pairs of three-drug regimens. Comparisons among the pairs of three-drug 
regimens are presented by Robbins et al. elsewhere in this issue of the Journal.6
METHODS
STUDY DESIGN
AIDS Clinical Trials Group (ACTG) study 384 was a multicenter, randomized, partially 
double-blind, controlled trial in which subjects were randomly assigned to six treatment 
groups. Groups 1, 2, 3, and 4 received two consecutive three-drug regimens. Groups 5 and 6 
each received a four-drug regimen (Fig. 1). The criteria for entry, study treatments, and 
procedures for informed consent, enrollment, and monitoring are described by Robbins et 
al.6
The primary objective of this portion of the study was the comparison of the use of four-
drug regimens with the use of two sequential three-drug regimens; comparisons were 
performed separately for the three-drug strategies starting with a regimen containing 
nelfinavir and those starting with a regimen containing efavirenz. The primary study end 
point was the failure of two consecutive three-drug regimens (groups 1, 2, 3, and 4), the 
failure of a single four-drug regimen (groups 5 and 6), or the premature discontinuation of 
the study treatment for any reason (Fig. 1). The secondary end points reported here are the 
length of time to the failure of the initial regimen, the time to virologic failure, the time to 
Shafer et al. Page 2













viral suppression, the time to the first severe toxic effect or toxic effect resulting in dose 
modification, the change in the CD4 cell count at weeks 48, 96, and 144, the self-reported 
level of adherence during the four days before selected clinic visits,7 and the occurrence of 
virologic failure accompanied by genotypic drug resistance.
The criterion for regimen failure due to virologic failure was a lack of adequate viral 
suppression or virologic rebound. The criterion for regimen failure due to toxicity was the 
occurrence of a toxic effect related to the study medications that could not be managed with 
the use of the permitted drug substitutions (stavudine for zidovudine or lamivudine for 
didanosine), reductions in the doses, or the temporary discontinuation of the use of a drug.6,8 
Peripheral neuropathy was assessed on the basis of a constellation of moderately severe 
symptoms (of grade 2 or higher) typically beginning in the distal portion of the legs, 
including pain, burning sensations, numbness, and paresthesias.
Testing for genotypic resistance was performed at the time of regimen failure, provided that 
the plasma HIV-1 RNA level was 1000 copies per milliliter or higher, with the use of the 
Trugene HIV-1 genotyping test (Visible Genetics). Genotypic resistance was defined by the 
acquisition of mutations that conferred definite resistance to a drug according to the 
manufacturer’s guidelines (version 4.0) at the time of the failure of the first or second 
regimen in groups 1, 2, 3, and 4 or the first regimen in groups 5 and 6.
STATISTICAL ANALYSIS
The general methods for the comparisons with respect to the primary end point and related 
time-to-event secondary end points are described by Robbins et al.6 In the comparison of the 
three-drug strategies, there was a significant interaction between the combination of 
nucleoside analogues used in the initial regimen and the use of nelfinavir or efavirenz in the 
initial regimen. For this reason, we report separate comparisons between the four-drug 
regimens and the three-drug strategies starting with regimens containing either efavirenz or 
nelfinavir according to the combination of nucleoside analogues used. We noted significant 
interactions. Therefore, the significance level for the testing of hypotheses and the 
estimation of confidence intervals was adjusted to 0.0125, reflecting the performance of four 
different comparisons addressing the same primary objective.9 Individual confidence 
intervals were calculated at 98.75 percent and are reported as adjusted 95 percent confidence 
intervals.
Post hoc comparisons were made between the groups receiving four drugs and those 
receiving two three-drug regimens with respect to the time to viral suppression and the 
occurrence of regimen failure accompanied by genotypic drug resistance. Additional post 
hoc analyses considered toxic effects during treatment with the first two study regimens in 
groups 1, 2, 3, and 4 and during treatment with the single study regimen in groups 5 and 6. 
Post hoc assessments of whether the hazard of a first toxic effect changed over time were 
performed with the use of likelihood-ratio tests comparing Weibull models with exponential 
models of survival. Exploratory subgroup analyses of the rates of the primary and related 
secondary end points according to the base-line CD4 cell count were performed in the 
following previously described subgroups: subjects with fewer than 200 CD4 cells per cubic 
millimeter, those with 200 to 350 cells per cubic millimeter, and those with more than 350 
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cells per cubic millimeter.4,5 Self-reported adherence was summarized as the percentage of 
the prescribed regimen taken during the scheduled sampling periods within the first 32 
weeks of study treatment.
RESULTS
BASE-LINE CHARACTERISTICS
There were 980 subjects included in the analysis: 155 each in groups 1, 2, 3, and 4, 178 in 
group 5, and 182 in group 6. A total of 898 subjects were enrolled in the United States, and 
82 in Italy. The median age was 36 years, and 82 percent of the subjects were male. The 
median base-line plasma HIV-1 RNA level was 4.9 log10 copies per milliliter, and the 
median CD4 cell count was 278 per cubic millimeter. The treatment groups were well 
balanced in terms of base-line characteristics (see Supplementary Appendix 1, available 
with the full text of this article at www.nejm.org).
STUDY FOLLOW-UP AND ADHERENCE
The median duration of follow-up was 28 months, and the median duration of treatment with 
study medication was 27 months. The mean self-reported level of adherence ranged from 
97.5 to 98.8 percent, with no significant differences among the six treatment groups. 
Stavudine was substituted for zidovudine in 25 subjects, and lamivudine was substituted for 
didanosine in 78 subjects.
PRIMARY END POINT
The primary end point was reached in 441 subjects (45.0 percent) including 272 in groups 1, 
2, 3, and 4 (43.9 percent) and 169 in groups 5 and 6 (46.9 percent) (Fig. 1). Among the 620 
subjects in the three-drug groups, the primary study end point was reached in 80 because of 
virologic or toxicity-related failure of the second three-drug regimen, and 192 subjects 
discontinued treatment prematurely for reasons other than protocol-defined virologic or 
toxicity-related failure.6 These 192 subjects included 82 who had virologic or toxicity-
related failure of their first regimen. Among the 360 subjects in the four-drug groups, the 
primary study end point was reached in 98 because of virologic failure (in 63 subjects) or 
toxicity-related failure (in 35 subjects), and 71 discontinued treatment prematurely for 
reasons other than protocol-defined virologic or toxicity-related failure.
There was no significant difference in the time to the primary end point between the group 
that received the four-drug regimen containing didanosine and stavudine and the group that 
received sequential three-drug regimens beginning with nelfinavir, didanosine, and 
stavudine (hazard ratio for the primary end point in the four-drug group as compared with 
the three-drug group, 1.24; adjusted 95 percent confidence interval, 0.82 to 1.87) or between 
the four-drug group that received zidovudine and lamivudine and the group that received 
sequential three-drug regimens beginning with nelfinavir, zidovudine, and lamivudine 
(hazard ratio, 1.06; adjusted 95 percent confidence interval, 0.71 to 1.58) (Fig. 2A, 2B, and 
2C). Similarly, there was no significant difference in the time to the primary end point 
between the group that received the four-drug regimen containing didanosine and stavudine 
and the group that received sequential three-drug regimens beginning with efavirenz, 
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didanosine, and stavudine (hazard ratio, 1.01; adjusted 95 percent confidence interval, 0.68 
to 1.50) or between the four-drug group that received zidovudine and lamivudine and the 
group that received sequential three-drug regimens beginning with efavirenz, zidovudine, 
and lamivudine (hazard ratio, 1.45; adjusted 95 percent confidence interval, 0.94 to 2.23) 
(Fig. 2A, 2D, and 2E).
FIRST REGIMEN FAILURE
The use of a four-drug regimen was associated with a longer time to the first regimen failure 
than the three-drug regimens containing nelfinavir, whether the subjects were assigned to 
start treatment with didanosine and stavudine (hazard ratio for first regimen failure in the 
four-drug group as compared with the three-drug group, 0.55; adjusted 95 percent 
confidence interval, 0.36 to 0.86) or with zidovudine and lamivudine (hazard ratio, 0.49; 
adjusted 95 percent confidence interval, 0.30 to 0.81) (Fig. 3A, 3B, and 3C). However, the 
results of the comparisons between the four-drug regimens and the three-drug regimens 
containing efavirenz depended on which nucleoside analogues were used (P=0.02 for the 
interaction between the number of drugs and the nucleoside analogues received). The four-
drug regimen was associated with a longer time to the first regimen failure than the three-
drug regimen containing efavirenz among the subjects who were randomly assigned to 
didanosine and stavudine (hazard ratio, 0.63; adjusted 95 percent confidence interval, 0.40 
to 0.98), but not among those who were assigned to zidovudine and lamivudine (hazard 
ratio, 1.21; adjusted 95 percent confidence interval, 0.67 to 2.20) (Fig. 3A, 3D, and 3E).
FIRST VIROLOGIC FAILURE
The four-drug regimens were associated with a longer time to the first virologic failure than 
the three-drug strategies beginning with a regimen containing nelfinavir, both among 
subjects who were assigned to begin treatment with didanosine and stavudine (hazard ratio 
for first virologic failure in the four-drug group as compared with the three-drug group, 
0.49; adjusted 95 percent confidence interval, 0.31 to 0.78) and among those assigned to 
begin treatment with zidovudine and lamivudine (hazard ratio, 0.41; adjusted 95 percent 
confidence interval, 0.25 to 0.68). However, the results of the comparisons between the 
four-drug regimens and the three-drug strategies beginning with regimens containing 
efavirenz depended on which nucleoside analogues were used (P=0.02 for the interaction). 
The four-drug regimen was associated with a longer time to the first virologic failure than 
the three-drug strategy beginning with a regimen containing efavirenz among subjects 
randomly assigned to receive didanosine and stavudine (hazard ratio, 0.57; adjusted 95 
percent confidence interval, 0.35 to 0.93), but not among those assigned to receive 
zidovudine and lamivudine (hazard ratio, 1.16; adjusted 95 percent confidence interval, 0.63 
to 2.14).
TIME TO VIRAL SUPPRESSION
Suppression of plasma HIV-1 RNA levels to a level below 50 copies per milliliter occurred 
faster in subjects randomly assigned to receive zidovudine, lamivudine, and efavirenz than 
among those assigned to the four-drug regimen containing zidovudine, lamivudine, 
efavirenz, and nelfinavir, but only among subjects in the highest stratum of HIV-1 RNA 
(≥5.0 log10 copies per milliliter) (P<0.001). This effect was not observed within other HIV-1 
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RNA strata or among the subjects randomly assigned to receive didanosine and stavudine; in 
fact, there was a significant interaction among the treatment factors (the use of four drugs or 
two three-drug regimens and the choice of nucleoside analogues) and the HIV-1 RNA strata 
(P=0.002). The cumulative proportions of subjects in whom viral suppression had been 
achieved by weeks 16 and 24 were 82 percent and 94 percent, respectively, among subjects 
randomly assigned to begin treatment with zidovudine, lamivudine, and efavirenz, as 
compared with 68 percent and 84 percent, respectively, among subjects randomly assigned 
to receive zidovudine, lamivudine, efavirenz, and nelfinavir (see Supplementary Appendix 
2, available with the full text of this article at www.nejm.org). The higher rate of viral 
suppression among the subjects who received zidovudine, lamivudine, and efavirenz did not 
appear to result from differential dropout rates among the treatment groups (data not 
shown).
CD4 CELL COUNTS
The median increase from base line in the CD4 cell count was 168 cells per cubic millimeter 
at week 48 (among 795 subjects), 251 cells per cubic millimeter at week 96 (712 subjects), 
and 295 cells per cubic millimeter at week 144 (401 subjects). There were no significant 
differences in the changes in the CD4 cell count according to the number of drugs used or 
the combination of nucleoside analogues used (data not shown).
DEATHS, SERIOUS ADVERSE EVENTS, AND TOXIC EFFECTS OF DRUGS
There were six deaths in the three-drug groups and six deaths in the four-drug groups. Three 
subjects died from myocardial infarction, two from opportunistic infection, two from cancer, 
one from cirrhosis, and one from trauma; the cause of death was uncertain in three subjects. 
There were 44 reported AIDS-defining events in 35 subjects; the incidence of a new 
diagnosis of AIDS or death was 2.1 per 100 person-years of follow-up. A lower base-line 
CD4 cell count and older age (but not a higher HIV-1 RNA stratum at screening or any 
treatment-group assignment) were independently associated with an increased risk of 
development of AIDS or death (data not shown).
Between 65 and 104 subjects from each of the six groups (42 to 58 percent) had a serious 
toxic effect (a severe toxic effect or a toxic effect resulting in dose modification) during 
treatment with their first regimen, and there was a significant difference across the six 
groups (P<0.001 by the log-rank test). Each of the three groups that began therapy with 
didanosine and stavudine had a higher incidence of serious toxic effects than the groups that 
began therapy with zidovudine and lamivudine. This observation prompted a post hoc 
comparison of the combinations of nucleoside analogues, which showed that the time to a 
serious toxic effect was shorter among subjects who began therapy with didanosine and 
stavudine than among those who began therapy with zidovudine and lamivudine (P<0.001).
Table 1 summarizes the incidence of selected toxic effects occurring before the primary end 
point according to the assigned treatment group. Peripheral neuropathy developed in 154 
subjects and was more common in the groups that began therapy with didanosine and 
stavudine than among those that began therapy with zidovudine and lamivudine (P<0.001). 
The risk of peripheral neuropathy was inversely correlated with the base-line CD4 cell count 
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(hazard ratio for peripheral neuropathy, 0.86 for every increment of 100 cells per cubic 
millimeter in the CD4 cell count; 95 percent confidence interval, 0.79 to 0.95). Among the 
subjects who began therapy with didanosine and stavudine, the risk of a first serious toxic 
effect decreased over time (P=0.001).
Post hoc analyses showed a greater risk of pancreatitis (P=0.005), elevated serum lipase 
levels (P=0.003), and hepatic abnormalities (P=0.004) among subjects who were randomly 
assigned to begin therapy with didanosine and stavudine than among those assigned to begin 
therapy with zidovudine and lamivudine (Table 1). The occurrence of lactic acidosis during 
treatment with study medications was reported in nine subjects, all of whom were receiving 
didanosine and stavudine. There was no significant difference in the time to a toxic effect 
according to whether subjects began therapy with nelfinavir, efavirenz, or both.
GENOTYPIC DRUG RESISTANCE
Mutations conferring resistance to nucleoside analogues were detected at positions 184 (in 
80 percent of cases), 74 (in 5 percent), 65 (in 3 percent), 215 (in 3 percent), 75 (in 1 
percent), and 151 (in 1 percent) and at more than one of these positions in 5 percent of 
subjects with nucleoside-analogue resistance. Resistance to nucleoside analogues developed 
in significantly fewer subjects in the four-drug group than in the three-drug group that began 
therapy with nelfinavir among subjects who began therapy with didanosine and stavudine 
(0.6 percent vs. 7.1 percent, P=0.001) and among those who began therapy with zidovudine 
and lamivudine (3.8 percent vs. 22.6 percent, P<0.001) (Fig. 4A). The effect of starting 
treatment with a four-drug regimen or a three-drug regimen containing efavirenz depended 
on the combination of nucleoside analogues used (P=0.003 for the interaction): resistance to 
nucleoside analogues developed in significantly fewer subjects in the four-drug group than 
in the three-drug group that began therapy with efavirenz among subjects who began therapy 
with didanosine and stavudine (0.6 percent vs. 16.1 percent, P<0.001) but not among those 
who began therapy with zidovudine and lamivudine (3.8 percent vs. 7.7 percent, P=0.12) 
(Fig. 4A). Among subjects in three-drug groups, those who began therapy with zidovudine, 
lamivudine, and efavirenz had fewer treatment failures with resistance to nucleoside 
analogues (7.7 percent) than those who began therapy with zidovudine, lamivudine, and 
nelfinavir (22.6 percent, P<0.001) or those who began therapy with didanosine, stavudine, 
and efavirenz (16.1 percent, P=0.02) (Fig. 4A).
Mutations conferring resistance to nonnucleoside reverse-transcriptase inhibitors were 
detected at positions 103 (in 72 percent of cases), 190 (in 6 percent), and 188 (in 3 percent) 
and at more than one of these positions in 19 percent of subjects with resistance to 
nonnucleoside reverse-transcriptase inhibitors. Resistance to nonnucleoside reverse-
transcriptase inhibitors developed in significantly fewer subjects in the four-drug group than 
in the three-drug group that began therapy with efavirenz among subjects who began therapy 
with didanosine and stavudine (10.7 percent vs. 23.9 percent, P=0.001) but not among those 
who began therapy with zidovudine and lamivudine (8.2 percent vs. 7.1 percent, P=0.69) 
(Fig. 4B). There was no significant difference in the rate of resistance to nonnucleoside 
reverse-transcriptase inhibitors between the four-drug groups and the three-drug groups that 
began therapy with nelfinavir (Fig. 4B). The results of comparisons among the three-drug 
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groups depended on the combination of nucleoside analogues used (P=0.006 for the 
interaction). Among the subjects in three-drug groups, resistance to non-nucleoside reverse-
transcriptase inhibitors developed in a higher proportion of those who began therapy with 
didanosine, stavudine, and efavirenz (23.9 percent) than of those who began therapy with 
didanosine, stavudine, and nelfinavir (5.2 percent, P<0.001) or those who began therapy 
with zidovudine, lamivudine, and efavirenz (7.1 percent, P< 0.001) (Fig. 4B).
Mutations conferring resistance to protease inhibitors were detected at positions 30 (in 61 
percent of cases), 90 (in 17 percent), 46 (in 7 percent), and 84 (in 3 percent) and at more 
than one of these positions in 12 percent of subjects with resistance to protease inhibitors. 
Resistance to protease inhibitors developed in fewer subjects in the four-drug group than in 
the three-drug group that began therapy with nelfinavir among subjects who began therapy 
with didanosine and stavudine (2.2 percent vs. 11.0 percent, P=0.001) and among those who 
began therapy with zidovudine and lamivudine (0.5 percent vs. 7.7 percent, P<0.001) (Fig. 
4C). There was no significant difference in the rate of resistance to protease inhibitors 
between the four-drug groups and the three-drug groups that began therapy with efavirenz 
(Fig. 4C).
DISCUSSION
This study compared different strategies for initiating antiretroviral therapy with four-drug 
and sequential three-drug regimens, with use of a composite primary end point of virologic 
rebound, toxic effects, or premature discontinuation of treatment, as well as seven secondary 
end points, including the change in the CD4 cell count, the first regimen failure (due to 
virologic rebound or toxic effects), the first virologic failure, the time to an undetectable 
HIV-1 RNA level, toxic effects, the level of adherence, and the development of drug 
resistance. Because no single surrogate end point has been validated as capturing the clinical 
benefit of prolonged treatment and because low rates of clinical events preclude the use of 
such end points for the investigation of first-line therapy, we looked for consistent results 
among the end points.
There was no significant difference in the duration of successful treatment, as measured in 
terms of the time to the primary end point, between the groups receiving a single four-drug 
regimen and those receiving two consecutive three-drug regimens, regardless of the 
combination of nucleoside analogues used in the initial regimen. There were also no 
significant differences between the four-drug groups and the three-drug groups in the 
changes in the CD4 cell count. The definition of the primary end point was designed to 
capture all possible reasons for the premature discontinuation of treatment in addition to 
virologic rebound and protocol-specified toxic effects. Because the primary end point was 
the time to the failure of drugs from all three classes, subjects receiving a four-drug regimen 
reached the primary end point when they had a single regimen failure (involving the use of 
only a single combination of nucleoside analogues).
In terms of the time to the secondary end points of the first regimen failure and the first 
virologic failure, the four-drug regimens were superior both to the three-drug strategies 
beginning with regimens containing nelfinavir and to therapy beginning with didanosine, 
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stavudine, and efavirenz, but not to therapy beginning with zidovudine, lamivudine, and 
efavirenz. There were relatively few first regimen failures during the three-year study in the 
group that began therapy with zidovudine, lamivudine, and efavirenz. The potency of this 
regimen was further demonstrated by the finding that the use of this regimen resulted in a 
shorter time to viral suppression than either of the four-drug regimens among subjects with 
the highest levels of HIV-1 RNA. Although the addition of nelfinavir to these three drugs 
provided no further benefit with respect to any end point, we cannot rule out the possibility 
that a different protease inhibitor might have been more effective.
There was no significant difference in the risk of toxic effects between the four-drug groups 
and the three-drug groups. Only the combination of nucleoside analogues used in the initial 
regimen significantly influenced the risk of toxic effects, with a higher incidence of 
peripheral neuropathy, pancreatitis, and hepatic enzyme abnormalities among subjects who 
began therapy with didanosine and stavudine than among those who began therapy with 
zidovudine and lamivudine. Preliminary data from a subgroup of subjects have also shown a 
greater degree of fat loss in the limbs among subjects who began therapy with didanosine 
and stavudine.10 All these toxic effects may result from mitochondrial dysfunction induced 
by nucleoside analogues.11–13
Antiretroviral regimens containing drugs from more than two classes are not routinely 
recommended for patients beginning antiretroviral therapy because of concern that patients 
in whom a three-class regimen fails may be at higher risk for drug resistance should 
virologic failure occur, leaving them with fewer options for subsequent therapy. However, 
we found that the cumulative proportion of regimen failures with genotypic resistance was 
often lower, and never higher, in the four-drug groups than in the three-drug groups.
Reported adherence was high in each of the six groups, suggesting that the study’s findings 
result from the intrinsic activity of the treatment regimens rather than from the patterns of 
adherence. Our findings, however, may not be applicable to persons who do not maintain 
high levels of adherence.14 Treatment failure and resistance to efavirenz and lamivudine are 
usually caused by mutations of a single amino acid,15,16 whereas resistance to protease 
inhibitors frequently requires multiple amino acid substitutions.4,17–20 In this study, subjects 
in whom regimens containing efavirenz failed often had amino acid substitutions that would 
also confer resistance to other nonnucleoside reverse-transcriptase inhibitors. In contrast, 
resistance to protease inhibitors was often associated with a mutation at position 30 of the 
protease gene that confers resistance to nelfinavir alone.
Although four-drug regimens were effective and did not lead to an increased risk of toxic 
effects or drug resistance, the simpler three-drug regimen consisting of zidovudine, 
lamivudine, and efavirenz emerged as the optimal choice for the initiation of therapy. This 
three-drug regimen was effective in achieving and maintaining viral suppression throughout 
the study and allowed most subjects who began therapy with this regimen to reserve 
protease-inhibitor therapy for the future. The fact that the addition of nelfinavir to this three-
drug regimen did not lead to more rapid viral suppression attests to the potency of this 
regimen; possible mechanisms underlying this potency are being explored in a 
pharmacologic substudy. Zidovudine, lamivudine, and efavirenz was the most effective of 
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the initial three-drug regimens in terms of delaying the first regimen failure,6 and this was 
also the only three-drug regimen that was not significantly different from the four-drug 
regimens in terms of the lengths of time to the first regimen failure and the first virologic 
failure.
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Figure 1. Study Design and Disposition of Subjects
Panel A shows the factorial design of the trial, with the treatment factors represented in 
terms of the initial treatment regimens. Panel B shows the numbers of subjects who were 
randomly assigned to each group, the numbers of virologic and toxicity-related regimen 
failures, and the numbers of premature discontinuations of study treatment. The primary 
study end point was defined as the failure of two consecutive regimens for subjects in 
groups 1, 2, 3, and 4 and the failure of a single regimen for subjects in groups 5 and 6. The 
premature discontinuation of all study treatment for any reason contributed to the primary 
study end point but not to the secondary end point of the first regimen failure. Panel C lists 
the criteria for regimen failure.
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Figure 2. Time to the Primary End Point
The Kaplan–Meier curves show the time to the primary study end point — failure of two 
consecutive three-drug regimens or a single four-drug regimen — in all treatment groups 
(Panel A) and in individual four-drug groups as compared with individual three-drug groups 
according to the drugs included in the initial regimen (Panels B, C, D, and E). The hazard 
ratios given are for the primary end point in the four-drug group as compared with the three-
drug group; adjusted 95 percent confidence intervals (CIs) were calculated in order to adjust 
the significance level to 0.0125 to account for the performance of four comparisons.
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Figure 3. Time to the First Regimen Failure
The Kaplan–Meier curves show the time to the first regimen failure in all treatment groups 
(Panel A) and in individual four-drug groups as compared with individual three-drug groups 
according to the drugs included in the initial regimen (Panels B, C, D, and E). Because most 
of the first regimen failures were due to virologic failure, the Kaplan–Meier curves for the 
time to the first virologic failure were similar to those shown here. The hazard ratios given 
are for the first regimen failure in the four-drug group as compared with the three-drug 
group; adjusted 95 percent confidence intervals (CIs) were calculated in order to adjust the 
significance level to 0.0125 to account for the performance of four comparisons.
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Figure 4. Proportions of Subjects Who Had Regimen Failure with Resistance to Nucleoside 
Analogues (Panel A), Nonnucleoside Reverse-Transcriptase Inhibitors (Panel B), and Protease 
Inhibitors (Panel C) According to Treatment Group
For subjects in groups 1, 2, 3, and 4, the bars show the cumulative proportions of subjects 
with drug resistance at the time of the first or second regimen failure; for subjects in groups 
5 and 6, the bars show the proportions of subjects with new drug-resistance mutations after 
the failure of their first regimen. Drug-resistance mutations were identified through the 
sequencing of the HIV-1 reverse transcriptase and protease of virus isolated from subjects 
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with virologic failure or toxicity-related failure who had plasma HIV-1 RNA levels of at 
least 1000 copies per milliliter.
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